Item 1.01. Entry into a Material Definitive Agreement.
Borrowings under the Shareholder's Loan Agreement will incur interest at the
applicable London Interbank Offer Rate ("LIBOR"), plus 4.5% per annum. Pursuant
to the Shareholder's Loan Agreement, the Company is restricted from using any
loan proceeds to pay any legal expenses where the invoice or budget from a
vendor exceeds
The foregoing description of the Shareholder's Loan Agreement is qualified in its entirety by the full text of the Shareholder's Loan Agreement, which is attached hereto as Exhibits 10.1 and incorporated by reference herein.
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an
Off-Balance Sheet Arrangement of a Registrant.
The information included in Item 1.01 of this report is incorporated by reference into this Item 2.03.
Item 5.07. Submission of Matters to a Vote of Security Holders.
On
Proposal No. 1: Election of Directors
The following nominees were elected to the Board for a one-year term expiring at the Company's 2022 Annual Meeting, as follows:
BROKER FOR AGAINST ABSTAIN NON-VOTES Shaojun Sun, Ph.D. 13,889,858 23,353 12,179 2,571,821 Hong He 13,879,398 33,813 12,179 2,571,821 Kenneth W. Landini 13,037,167 875,044 13,179 2,571,821 Xinghao Li 13,867,445 33,569 24,376 2,571,821 Sidong Shao 13,867,441 33,543 24,406 2,571,821 Frank P. Simpkins 13,043,845 868,396 13,149 2,571,821 Guogang Wu 13,867,045 33,939 24,406 2,571,821
--------------------------------------------------------------------------------
Proposal No. 2: Ratification of Appointment of
The ratification of
FOR AGAINST ABSTAIN 16,487,728 4,223 5,260
Proposal No. 3: Approval, on an Advisory, Non-binding Basis, the Compensation of the Company's Named Executive Officers
The Company's named executive officer compensation was approved on an advisory, non-binding basis, as follows:
BROKER FOR AGAINST ABSTAIN NON-VOTES 13,866,339 42,350 16,701 2,571,821
Item 7.01 Regulation FD Disclosure.
On
The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933 (the "Securities Act") or the Exchange Act, except as shall be expressly set forth by reference in such a filing.
Caution Regarding Forward-Looking Statements
This Form 8-K contains forward-looking statements regarding the current
expectations of the Company about its prospects and opportunities. These
forward-looking statements are entitled to the safe-harbor provisions of
Section 21E of the Exchange Act. The Company has tried to identify these
forward-looking statements by using words such as "anticipate," "believe,"
"budgeted," "contemplate," "estimate," "expect," "forecast," "guidance," "may,"
"outlook," "plan," "projection," "should," "target," "will," "would," or similar
expressions, but these words are not the exclusive means for identifying such
statements. These statements are subject to a number of risks, uncertainties,
and assumptions that may cause actual results, performance or achievements to be
materially different from those expressed in, or implied by, such statements.
The Company cautions that the risks, uncertainties and other factors that could
cause its actual results to differ materially from those expressed in, or
implied by, the forward-looking statements, include, without limitation: the
impact of the ongoing COVID-19 pandemic could have on the Company's business and
financial results; the Company's ability to continue as a going concern; the
Company's ability to raise additional capital when needed and its liquidity;
uncertainties around the Company's ability to meet funding conditions under its
financing arrangements and access to capital thereunder; the potential
acceleration of the maturity at any time of the loans under the Company's
uncommitted senior secured revolving credit facility through the exercise by
Standard Chartered Bank of its demand right; the timing of completion of steps
to address, and the inability to address and remedy, material weaknesses; the
identification of additional material weaknesses or significant deficiencies;
risks related to complying with the terms and conditions of the settlements with
the
--------------------------------------------------------------------------------
coverage; the ability of the Company to accurately forecast sales, and the
extent to which sales result in recorded revenues; changes in customer demand
for the Company's products; volatility in oil and gas prices; the impact of
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Exhibit No. Description 10.1 Shareholder's Loan Agreement, dated as ofJuly 14, 2021 , between the Company andWeichai America Corp. 99.1 Press Release, datedJuly 20, 2021 , announcing the additional$25 million shareholder loan agreement between the Company andWeichai America Corp.
--------------------------------------------------------------------------------
© Edgar Online, source